SXTP (60 Degrees Pharmaceuticals) 3-Year EBITDA Growth Rate : -80.50% (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals 3-Year EBITDA Growth Rate?

60 Degrees Pharmaceuticals's EBITDA per Share for the three months ended in Sep. 2024 was $-0.88.

During the past 12 months, 60 Degrees Pharmaceuticals's average EBITDA Per Share Growth Rate was -2121.30% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -80.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of 60 Degrees Pharmaceuticals was -80.50% per year. The lowest was -80.50% per year. And the median was -80.50% per year.

Competitive Comparison of 60 Degrees Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.

60 Degrees Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

60 Degrees Pharmaceuticals (NAS:SXTP) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

60 Degrees Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

60 Degrees Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.

Executives

Geoffrey S Dow	director, 10 percent owner, officer: CEO and President	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Cheryl Xu	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Charles W Allen	director	1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc.	10 percent owner	824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Paul Field	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller	officer: Chief Financial Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc.	10 percent owner	200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith	officer: Chief Medical Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey	director	1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036